2007 JASN IMPACT FACTOR 7.111	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kshirsagar, A. V. Articles by Finn, W. F. Search for Related Content PubMed PubMed Citation Articles by Kshirsagar, A. V. Articles by Finn, W. F. Related Collections Related Article

N-Acetylcysteine for the Prevention of Radiocontrast Induced Nephropathy: A Meta-Analysis of Prospective Controlled Trials

Abhijit V. Kshirsagar^*, Charles Poole, Amy Mottl^*,, David Shoham^*,, Nora Franceschini^*,, Gail Tudor, Malay Agrawal, Cindy Denu-Ciocca^*, E. Magnus Ohman^, and William F. Finn^*

*Division of Nephrology and Hypertension, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; Department of Epidemiology, School of Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; Department of Biostatistics, School of Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; and Division of Cardiology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.

Correspondence to Dr. Abhijit V. Kshirsagar, CB 7155, 348 MacNider Hall, Chapel Hill, NC 27599-7155. Phone: 919-966-2561, ext. 259; Fax: 919-966-4251; E-mail: sagar{at}med.unc.edu

ABSTRACT. N-acetylcysteine has been recommended for patients with renal insufficiency who are to receive radiocontrast media. However, trials of oral N-acetylcysteine for the prevention of radiocontrast-induced nephropathy have yielded inconsistent results. A systematic review of patient and study characteristics was undertaken to discover possible explanations of the inconsistencies. The databases MEDLINE, EMBASE, and CENTRAL (1966 to March 2003) were searched in all languages, and conference proceedings from several professional societies from the years 1999 to 2003 were also searched. Only prospective controlled trials of oral N-acetylcysteine were included. Risk difference estimates and 95% confidence intervals were calculated. The estimates were examined for evidence of publication bias and heterogeneity. Stratified and meta-regression analyses were used to compare estimates by study and patient characteristics. Identified were 16 studies, 15 published and 1 unpublished. There was no evidence of publication bias, but there was substantial evidence of heterogeneity, thus precluding reliance on a meaningful summary effect estimate. Meta-regression identified several patient and study characteristics, with some evidence of association with study-specific estimates. None of these characteristics, however, formed subsets of studies with results that were homogeneous enough to aggregate. Research on N-acetylcysteine and the incidence of radiocontrast nephropathy is too inconsistent at present to warrant a conclusion on efficacy or a recommendation for its routine use. Identified patient and study characteristics may be responsible for some, but not all, of this inconsistency. A large, randomized, placebo-controlled trial, a pooled analysis of patient-level data, or both may resolve this issue.

Related Article

This Month’s Highlights
J. Am. Soc. Nephrol. 2004 15: A24-A26. [Full Text] [PDF]

This article has been cited by other articles:

				C C Geddes and G M Baxter Renal impairment Imaging, March 1, 2008; 20(1): 1 - 19. [Abstract] [Full Text] [PDF]

				M. H. Rosner, D. Portilla, and M. D. Okusa Analytic Reviews: Cardiac Surgery as a Cause of Acute Kidney Injury: Pathogenesis and Potential Therapies J Intensive Care Med, January 1, 2008; 23(1): 3 - 18. [Abstract] [PDF]

				S. Fishbane N-Acetylcysteine in the Prevention of Contrast-Induced Nephropathy Clin. J. Am. Soc. Nephrol., January 1, 2008; 3(1): 281 - 287. [Abstract] [Full Text] [PDF]

				G. T. C. Wong and M. G. Irwin Contrast-induced nephropathy Br. J. Anaesth., October 1, 2007; 99(4): 474 - 483. [Abstract] [Full Text] [PDF]

				A. Levin, G. E. Pate, S. Shalansky, A. Al-Shamari, J. G. Webb, C. E. Buller, and K. H. Humphries N-acetylcysteine reduces urinary albumin excretion following contrast administration: evidence of biological effect Nephrol. Dial. Transplant., September 1, 2007; 22(9): 2520 - 2524. [Abstract] [Full Text] [PDF]

				P. Schmidt, D. Pang, D. Nykamp, G. Knowlton, and H. Jia N-Acetylcysteine and Sodium Bicarbonate Versus N-Acetylcysteine and Standard Hydration for the Prevention of Radiocontrast-Induced Nephropathy Following Coronary Angiography Ann. Pharmacother., January 1, 2007; 41(1): 46 - 50. [Abstract] [Full Text] [PDF]

				P. A. McCullough, M. E. Bertrand, J. A. Brinker, and F. Stacul A Meta-Analysis of the Renal Safety of Isosmolar Iodixanol Compared With Low-Osmolar Contrast Media J. Am. Coll. Cardiol., August 15, 2006; 48(4): 692 - 699. [Abstract] [Full Text] [PDF]

				G. Marenzi, E. Assanelli, I. Marana, G. Lauri, J. Campodonico, M. Grazi, M. De Metrio, S. Galli, F. Fabbiocchi, P. Montorsi, et al. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. N. Engl. J. Med., June 29, 2006; 354(26): 2773 - 2782. [Abstract] [Full Text] [PDF]

				N. Pannu, N. Wiebe, M. Tonelli, and for the Alberta Kidney Disease Network Prophylaxis Strategies for Contrast-Induced Nephropathy JAMA, June 21, 2006; 295(23): 2765 - 2779. [Abstract] [Full Text] [PDF]

				M. Tepel, P. Aspelin, and N. Lameire Contrast-Induced Nephropathy: A Clinical and Evidence-Based Approach Circulation, April 11, 2006; 113(14): 1799 - 1806. [Full Text] [PDF]

				G. G L Biondi-Zoccai, M. Lotrionte, A. Abbate, L. Testa, E. Remigi, F. Burzotta, M. Valgimigli, E. Romagnoli, F. Crea, and P. Agostoni Compliance with QUOROM and quality of reporting of overlapping meta-analyses on the role of acetylcysteine in the prevention of contrast associated nephropathy: case study BMJ, January 28, 2006; 332(7535): 202 - 209. [Abstract] [Full Text] [PDF]

				B. J. Barrett and P. S. Parfrey Preventing Nephropathy Induced by Contrast Medium N. Engl. J. Med., January 26, 2006; 354(4): 379 - 386. [Full Text] [PDF]

				S. M. Bagshaw, F. A. McAlister, B. J. Manns, and W. A. Ghali Acetylcysteine in the Prevention of Contrast-Induced Nephropathy: A Case Study of the Pitfalls in the Evolution of Evidence Arch Intern Med, January 23, 2006; 166(2): 161 - 166. [Abstract] [Full Text] [PDF]

				M. H. Rosner and M. D. Okusa Acute Kidney Injury Associated with Cardiac Surgery Clin. J. Am. Soc. Nephrol., January 1, 2006; 1(1): 19 - 32. [Abstract] [Full Text] [PDF]

				S J Shalansky, G E Pate, A Levin, and J G Webb N-acetylcysteine for prevention of radiocontrast induced nephrotoxicity: the importance of dose and route of administration Heart, August 1, 2005; 91(8): 997 - 999. [Abstract] [Full Text] [PDF]

				V O Gomes, C E Poli de Figueredo, P Caramori, R Lasevitch, L C Bodanese, A Araujo, A P Roedel, A P Caramori, F S Brito Jr, H G Bezerra, et al. N-acetylcysteine does not prevent contrast induced nephropathy after cardiac catheterisation with an ionic low osmolality contrast medium: a multicentre clinical trial Heart, June 1, 2005; 91(6): 774 - 778. [Abstract] [Full Text] [PDF]

				R. W. Katzberg Contrast Medium-induced Nephrotoxicity: Which Pathway? Radiology, June 1, 2005; 235(3): 752 - 755. [Full Text] [PDF]

				I. Goldenberg and S. Matetzky Nephropathy induced by contrast media: pathogenesis, risk factors and preventive strategies Can. Med. Assoc. J., May 24, 2005; 172(11): 1461 - 1471. [Abstract] [Full Text] [PDF]

				S. M. Bagshaw and W. A. Ghali Theophylline for Prevention of Contrast-Induced Nephropathy: A Systematic Review and Meta-analysis Arch Intern Med, May 23, 2005; 165(10): 1087 - 1093. [Abstract] [Full Text] [PDF]

				M. Stafford-Smith Evidence-Based Renal Protection in Cardiac Surgery Seminars in Cardiothoracic and Vascular Anesthesia, March 1, 2005; 9(1): 65 - 76. [Abstract] [PDF]

				S. D. Weisbord and P. M. Palevsky Radiocontrast-Induced Acute Renal Failure J Intensive Care Med, March 1, 2005; 20(2): 63 - 75. [Abstract] [PDF]

				M. Maeder, M. Klein, T. Fehr, and H. Rickli Contrast nephropathy: Review focusing on prevention J. Am. Coll. Cardiol., November 2, 2004; 44(9): 1763 - 1771. [Abstract] [Full Text] [PDF]

				J. H. Ix, C. E. McCulloch, and G. M. Chertow Theophylline for the prevention of radiocontrast nephropathy: a meta-analysis Nephrol. Dial. Transplant., November 1, 2004; 19(11): 2747 - 2753. [Abstract] [Full Text] [PDF]

				M. A. Bettmann Frequently Asked Questions: Iodinated Contrast Agents RadioGraphics, October 1, 2004; 24(suppl_1): S3 - S10. [Abstract] [Full Text] [PDF]

				G. M. Chertow Prevention of Radiocontrast Nephropathy: Back to Basics JAMA, May 19, 2004; 291(19): 2376 - 2377. [Full Text] [PDF]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673